Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$217.83 -0.4%	$208.25	$181.73 ▼ $244.81	$384.85B	0.32	6.91 million shs	7.58 million shs
HIMS Hims & Hers Health	$26.12 +2.9%	$24.03	$13.74 ▼ $70.43	$6.05B	2.43	31.90 million shs	20.54 million shs
LLY Eli Lilly and Company	$1,105.37 -1.9%	$952.15	$623.78 ▼ $1,149.10	$1.04T	0.48	3.21 million shs	4.58 million shs
NVO Novo Nordisk A/S	$45.57 +0.1%	$40.81	$35.12 ▼ $81.44	$203.49B	0.77	20.86 million shs	10.95 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.50%	+1.77%	+10.52%	-5.62%	+19.50%
HIMS Hims & Hers Health	+0.65%	+5.93%	-9.17%	+75.13%	-52.47%
LLY Eli Lilly and Company	+3.81%	+8.14%	+28.89%	+7.26%	+56.79%
NVO Novo Nordisk A/S	+2.06%	+2.53%	+10.51%	+21.37%	-33.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$217.83 -0.4%	$208.25	$181.73 ▼ $244.81	$384.85B	0.32	6.91 million shs	7.58 million shs
HIMS Hims & Hers Health	$26.12 +2.9%	$24.03	$13.74 ▼ $70.43	$6.05B	2.43	31.90 million shs	20.54 million shs
LLY Eli Lilly and Company	$1,105.37 -1.9%	$952.15	$623.78 ▼ $1,149.10	$1.04T	0.48	3.21 million shs	4.58 million shs
NVO Novo Nordisk A/S	$45.57 +0.1%	$40.81	$35.12 ▼ $81.44	$203.49B	0.77	20.86 million shs	10.95 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.50%	+1.77%	+10.52%	-5.62%	+19.50%
HIMS Hims & Hers Health	+0.65%	+5.93%	-9.17%	+75.13%	-52.47%
LLY Eli Lilly and Company	+3.81%	+8.14%	+28.89%	+7.26%	+56.79%
NVO Novo Nordisk A/S	+2.06%	+2.53%	+10.51%	+21.37%	-33.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$253.43	16.34% Upside
HIMS Hims & Hers Health	2.12	Hold	$28.70	9.88% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.00	11.00% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	43.86% Upside

Current Analyst Ratings Breakdown

Latest HIMS, NVO, LLY, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/26/2026	LLY Eli Lilly and Company	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,133.00 ➝ $1,251.00
5/26/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,119.00
5/26/2026	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $25.00
5/22/2026	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
5/22/2026	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$18.00 ➝ $23.00
5/22/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,283.00
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$1,300.00 ➝ $1,330.00
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/19/2026	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$30.00 ➝ $28.00

(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	6.29	$15.32 per share	14.22	($3.74) per share	-58.24
HIMS Hims & Hers Health	$2.35B	2.58	$0.87 per share	30.11	$1.93 per share	13.53
LLY Eli Lilly and Company	$65.18B	15.97	$25.66 per share	43.08	$33.13 per share	33.36
NVO Novo Nordisk A/S	$46.80B	4.35	$4.80 per share	9.50	$7.12 per share	6.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$2.03	107.30	13.36	0.74	5.79%	-576.45%	13.39%	7/30/2026 (Estimated)
HIMS Hims & Hers Health	$128.37M	-$0.09	N/A	53.31	48.90	-0.56%	6.10%	1.52%	8/10/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	39.27	24.94	1.18	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.70	13.25	3.97	37.23%	63.31%	22.19%	8/5/2026 (Estimated)

Latest HIMS, NVO, LLY, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/11/2026	Q1 2026	HIMS Hims & Hers Health	$0.04	-$0.40	-$0.44	-$0.40	$616.84 million	$608.10 million
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/29/2026	Q1 2026	ABBV AbbVie	$2.59	$2.65	+$0.06	$0.39	$14.72 billion	$15.00 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	3.16%	+6.80%	340.89%	53 Years
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.61%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.75	3.85%	+21.74%	41.08%	N/A

Latest HIMS, NVO, LLY, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.80	0.68
HIMS Hims & Hers Health	2.18	1.69	1.56
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
HIMS Hims & Hers Health	11.76%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
HIMS Hims & Hers Health	2,442	231.46 million	204.24 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

HIMS, NVO, LLY, and ABBV Headlines

Recent News About These Companies

CVS Restores Coverage for Lilly's Zepbound

May 28 at 7:32 PM | finance.yahoo.com

Eli Lilly Jumps as CVS Expands Weight-Loss Drug Coverage

May 28 at 7:32 PM | finance.yahoo.com

Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables

May 28 at 2:30 PM | proactiveinvestors.com

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

May 28 at 2:30 PM | fool.com

Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher.

May 28 at 2:30 PM | finance.yahoo.com

CVS will add these weight-loss options to drug plans

May 28 at 2:30 PM | usatoday.com

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? (NVO)

...

May 28 at 9:10 AM | marketbeat.com

Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables

May 28 at 9:07 AM | proactiveinvestors.co.uk

LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call

May 28 at 8:00 AM | stocktwits.comS

Felix Offers Ozempic at Generic-Level Pricing as Lower-Cost GLP-1 Demand Remains Elevated Across Canada

May 28 at 8:00 AM | finance.yahoo.com

CVS Caremark adds Zepbound and Foundayo to formulary

May 28 at 8:00 AM | qz.comQ

Small biotech firms quicker to 'latch onto' AI than big ones, says Tencent Healthcare President

May 28 at 8:00 AM | finance.yahoo.com

Smith Chas P & Associates PA Cpas Increases Stake in Novo Nordisk A/S $NVO

May 28 at 6:16 AM | marketbeat.com

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

May 27 at 6:00 PM | fool.com

Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion

May 27 at 6:00 PM | finance.yahoo.com

Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now

May 27 at 6:00 PM | finance.yahoo.com

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions

May 27 at 12:57 PM | finance.yahoo.com

Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?

May 27 at 12:57 PM | finance.yahoo.com

Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot

May 27 at 12:57 PM | finance.yahoo.com

Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?

May 27 at 11:37 AM | zacks.com

Glenview Trust Co Cuts Stock Holdings in Novo Nordisk A/S $NVO

May 27 at 4:04 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HIMS, NVO, LLY, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$217.83 -0.80 (-0.37%)

Closing price 03:59 PM Eastern

Extended Trading

$216.74 -1.08 (-0.50%)

As of 04:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Hims & Hers Health NYSE:HIMS

$26.12 +0.74 (+2.92%)

Closing price 03:59 PM Eastern

Extended Trading

$26.20 +0.08 (+0.33%)

As of 04:58 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$1,105.37 -21.43 (-1.90%)

Closing price 03:59 PM Eastern

Extended Trading

$1,105.18 -0.19 (-0.02%)

As of 04:57 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$45.57 +0.06 (+0.14%)

Closing price 03:59 PM Eastern

Extended Trading

$45.60 +0.03 (+0.06%)

As of 04:57 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIMS, NVO, LLY, and ABBV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIMS, NVO, LLY, and ABBV Earnings

Compare Dividends

Latest HIMS, NVO, LLY, and ABBV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIMS, NVO, LLY, and ABBV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIMS, NVO, LLY, and ABBV Company Descriptions

AbbVie NYSE:ABBV

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools